^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imjudo (tremelimumab-actl)

    i
    Other names: PF06753388, CP675206, CP 675206, CP-675206, CP-675,206, CP-675, PF-06753388, CP 675, CP675, PF 06753388
    Company:
    AstraZeneca, Pfizer
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    4d
    KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma. (PubMed, Eur Urol)
    CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Also, an increase in KIM-1 during therapy was linked to worse progression-free survival (HR 1.7; 95% CI, 1.13-2.58; p = 0.01) and OS (HR 1.95; 95% CI, 1.23-3.08; p = 0.004) in ccRCC. This exploratory analysis supports the utility of KIM-1 in advanced ccRCC and pRCC.
    Journal • PD(L)-1 Biomarker
    |
    KIM1 (Kidney injury molecule 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Orpathys (savolitinib)
    6d
    INFINITY: TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Not yet recruiting --> Active, not recruiting
    Enrollment closed • MSI-H
    |
    MSI-H/dMMR
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    7d
    Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma. (PubMed, J Immunother Cancer)
    Our findings reveal regimen-specific systemic immune mechanisms in advanced HCC: Atez/Bev amplifies monocyte-NK cytotoxic axes, whereas Dur/Tre enhances monocyte-T cell inflammatory networks and TCR repertoire diversity. These insights highlight distinct predictive biomarkers and support regimen-tailored immunotherapy in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PRKCH (Protein Kinase C Eta) • CD14 (CD14 Molecule) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    8d
    TRITON: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Phase classification: P3 --> P2 | N=280 --> 100 | Trial completion date: Mar 2031 --> Dec 2027 | Trial primary completion date: Aug 2027 --> Dec 2026
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • pemetrexed
    9d
    D907HC00001: A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. (2025-521639-34-00)
    P1, N=4, Not yet recruiting, AstraZeneca AB
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • ceralasertib (AZD6738)
    11d
    Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens (clinicaltrials.gov)
    P1, N=153, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jan 2026 --> Dec 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    19d
    Favorable Response to Chemotherapy with Durvalumab plus Tremelimumab in Two Cases of KRAS G12C-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report. (PubMed, Intern Med)
    They thereafter achieved excellent clinical outcomes, including complete and partial responses, with sustained benefits. The POSEIDON regimen may represent a potent therapeutic option for this rare patient population with multiple negative prognostic factors.
    Journal • PD(L)-1 Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    19d
    Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=220, Recruiting, Riboscience, LLC. | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • RBS2418
    28d
    Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study (clinicaltrials.gov)
    P=N/A, N=1200, Completed, AstraZeneca | Recruiting --> Completed | N=300 --> 1200 | Trial completion date: Dec 2026 --> Jul 2025 | Trial primary completion date: Dec 2026 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    28d
    NRG-GY021: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (clinicaltrials.gov)
    P2, N=61, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date • Tumor mutational burden • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Imjudo (tremelimumab-actl)
    1m
    DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma. (PubMed, Nat Commun)
    Partial response was observed in 7/11 (63.64%) patients with concurrent DNA damage repair gene mutations in the immunotherapy arm. As a prospective study in PDAC identifying a potential biomarker beyond mismatch repair deficiency for benefit from immunotherapy, these data highlight an actionable subgroup of mPDAC.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • ATM (ATM serine/threonine kinase) • FANCA (FA Complementation Group A)
    |
    BRCA1 mutation • ATM mutation
    |
    Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl)
    1m
    Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden • IO biomarker
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MSH6 (MutS homolog 6)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)